将生物标志物个体化治疗反应评估整合到贝叶斯试验设计以实现癌症个体化治疗
研究提出一种贝叶斯试验框架,利用患者生物标志物信息与历史生物标志物效应数据优化放疗剂量分配,并在直肠癌器官保留场景中通过全模拟试验评估可行性与统计性能。模拟显示部分患者亚组从适度剂量提升获益最大,乐观先验下不足100例模拟患者即可声称自适应剂量获益,弱信息先验下需不足150例。
要点
- 贝叶斯反应自适应设计可将ERI等生物标志物整合进放疗个体化剂量优化。
- 模拟中仅一个亚组从适度剂量提升获得肿瘤控制改善且毒性可接受。
- 乐观先验下不足100例、弱信息先验下不足150例模拟患者即可评估获益。
核心结论
- 该贝叶斯反应自适应设计为将ERI等生物标志物整合进放疗个体化提供了定量框架,可结构化评估剂量-反应关系,并可能促进生物标志物发现向局部癌症治疗转化,但需承认底层模型假设。
研究设计与样本
- 设计为前瞻性两臂贝叶斯反应自适应试验概念,纳入最优停止原则,以治疗中生物标志物测量指导剂量调整,并以影像衍生的早期回归指数(ERI)为例说明。
- 通过直肠癌器官保留场景的全模拟试验评估可行性与统计性能,并对先验信息对后验分布的影响进行敏感性分析。
主要发现
- 模拟使用生物标志物依赖的肿瘤控制曲线与生物标志物非依赖的毒性曲线建模患者反应。
- 一个患者亚组从适度剂量提升获益最大,获得肿瘤控制改善且无过度毒性。
- 差反应者与优反应者在临床可接受剂量下额外获益有限。
- 乐观先验场景下所提设计可以不足100例模拟患者声称自适应剂量获益,弱信息先验下需不足150例患者。
关键数值与推荐
- 乐观先验场景下,所提设计以不足100例模拟患者声称自适应剂量获益。
- 弱信息先验场景下,需不足150例模拟患者。
临床怎么用
- 在直肠癌器官保留放疗中,可依据治疗中ERI等生物标志物测量进行反应自适应剂量调整,并以贝叶斯框架结构化评估剂量-反应关系。
局限性
- 结论需承认底层模型假设。
- 可行性及统计性能基于全模拟试验评估,而非真实临床试验数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Biomarker-driven strategies are central to personalized oncology, yet local treatments such as radiotherapy still lack validated stratification frameworks. Conventional frequentist trial designs often require prohibitively large patient cohorts without incorporating previously validated data. We therefore propose a Bayesian trial framework, which utilizes information of a patient's biomarker and historical information of the biomarker effect to optimize the assigned dose. The aim of this work is to develop and illustrate such a framework for radiotherapy in rectal cancer organ preservation. METHODS: We designed a prospective two-arm Bayesian response-adaptive trial concept incorporating the principle of optimal stopping. Biomarker measurements obtained during treatment guided dose adaptation, illustrated here using the imaging-derived early regression index (ERI). Feasibility and statistical performance were evaluated through a fully simulated trial in rectal cancer organ preservation. Sensitivity analysis was applied to investigate the effect of prior information on the posterior distribution. RESULTS: Simulations modeled the patients' response using biomarker-dependent tumor control and biomarker-independent toxicity curves. One subgroup of patients would benefit most from moderate dose escalation, achieving improved tumor control without excessive toxicity. In contrast, poor and excellent responders gained limited additional benefit at clinically acceptable doses. Under the optimistic prior scenario, the proposed design could claim the benefit of the adaptive dose with fewer than 100 simulated patients, while with weakly informative priors less than 150 patients are needed. CONCLUSION: This Bayesian response-adaptive design provides a quantitative framework to integrate biomarkers such as ERI into radiotherapy personalization. It enables a structured evaluation of dose-response relationships and may help facilitate the translation of biomarker findings into local cancer therapy, acknowledging the underlying model assumptions.
引用
- Kolias P, Ajdari A, Cicchetti A, et al. Integrating biomarker-derived individual treatment response assessment into Bayesian trial design for personalized cancer treatment. Radiother Oncol. 2026. PMID: 41831619. doi:10.1016/j.radonc.2026.111484
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。